Literature DB >> 11426063

Topoisomerase II poisoning by indazole and imidazole complexes of ruthenium.

Y N Vashisht Gopal1, A K Kondapi.   

Abstract

Trans-imidazolium (bis imidazole) tetrachloro ruthenate (RuIm) and trans-indazolium (bis indazole) tetrachloro ruthenate (RuInd) are ruthenium coordination complexes, which were first synthesized and exploited for their anticancer activity. These molecules constitute two of the few most effective anticancer ruthenium compounds. The clinical use of these compounds however was hindered due to toxic side effects on the human body. Our present study on topoisomerase II poisoning by these compounds shows that they effectively poison the activity of topoisomerase II by forming a ternary cleavage complex of DNA, drug and topoisomerase II. The thymidine incorporation assays show that the inhibition of cancer cell proliferation correlates with topoisomerase II poisoning. The present study on topoisomerase II poisoning by these two compounds opens a new avenue for renewing further research on these compounds. This is because they could be effective lead candidates for the development of more potent and less toxic ruthenium containing topoisomerase II poisons. Specificity of action on this molecular target may reduce the toxic effects of these ruthenium-containing molecules and thus improve their therapeutic index.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11426063     DOI: 10.1007/BF02703651

Source DB:  PubMed          Journal:  J Biosci        ISSN: 0250-5991            Impact factor:   1.826


  19 in total

1.  Chromosome assembly in vitro: topoisomerase II is required for condensation.

Authors:  Y Adachi; M Luke; U K Laemmli
Journal:  Cell       Date:  1991-01-11       Impact factor: 41.582

Review 2.  DNA topoisomerases: why so many?

Authors:  J C Wang
Journal:  J Biol Chem       Date:  1991-04-15       Impact factor: 5.157

3.  Purification and functional characterization of type II DNA topoisomerase from rat testis and comparison with topoisomerase II from liver.

Authors:  S Galande; K Muniyappa
Journal:  Biochim Biophys Acta       Date:  1996-07-31

Review 4.  DNA topoisomerases.

Authors:  J C Wang
Journal:  Annu Rev Biochem       Date:  1985       Impact factor: 23.643

5.  Structure and mechanism of DNA topoisomerase II.

Authors:  J M Berger; S J Gamblin; S C Harrison; J C Wang
Journal:  Nature       Date:  1996-01-18       Impact factor: 49.962

Review 6.  Structure and function of type II DNA topoisomerases.

Authors:  P M Watt; I D Hickson
Journal:  Biochem J       Date:  1994-11-01       Impact factor: 3.857

7.  A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells/.

Authors:  C S Downes; D J Clarke; A M Mullinger; J F Giménez-Abián; A M Creighton; R T Johnson
Journal:  Nature       Date:  1994-12-01       Impact factor: 49.962

8.  Inhibition of topoisomerase II catalytic activity by two ruthenium compounds: a ligand-dependent mode of action.

Authors:  Y N Gopal; D Jayaraju; A K Kondapi
Journal:  Biochemistry       Date:  1999-04-06       Impact factor: 3.162

9.  Topoisomerase II is a cellular target for antiproliferative cobalt salicylaldoxime complex.

Authors:  D Jayaraju; Y N Gopal; A K Kondapi
Journal:  Arch Biochem Biophys       Date:  1999-09-01       Impact factor: 4.013

10.  DNA topoisomerase II from Drosophila melanogaster. Relaxation of supercoiled DNA.

Authors:  N Osheroff; E R Shelton; D L Brutlag
Journal:  J Biol Chem       Date:  1983-08-10       Impact factor: 5.157

View more
  1 in total

1.  Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019.

Authors:  Caroline Bartel; Alexander E Egger; Michael A Jakupec; Petra Heffeter; Markus Galanski; Walter Berger; Bernhard K Keppler
Journal:  J Biol Inorg Chem       Date:  2011-06-26       Impact factor: 3.862

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.